I said, "{{Something happened during lower animal trial: Bavituximab without a payload, "naked" Bavi- was noted to be immunogenic, stimulating the body's immune system. With that discovery PPHM scientists moved that direction, toward immunological attack. In my mind that was an error, Immunocancer warfare is a splendid and idealistic avenue of inquiry. Immunotherapy WORKS. But it isn't the atom bomb against that calibre opponent. Rhetorically I asked, "What happened to loaded Bavi?" I can't recall any information from PPHM about what happened to that program? Pfizer at UCSF (northern California) has announced revisiting that strategy...and for a very good reason. We need the bomb. I said, "Rumor has it that when one arm of Bavi is loaded with a small molecule, the other "available" arm cannot bind so readily or solidly to target. }}
You said, "Drug conjugates for MAbs can be linked to various portions of the Ab. In fact, multiple conjugates can be added to a single MAb to make it an extremely potent delivery vehicle. If PPHM tried to arm Bavi on one of the variable arms, saw it lose specificity or avidity then stopped rather than try and move the conjugate to other parts of the Ab, like the Fc portion, then they are imbeciles."
THIS IS IMPORTANT.
We know -PS investigators are not imbeciles (come on!), so we can assume the variables have been shepherded into labby notebooks. PPHM apparently has the warship that can take it to cancer. Let's keep moving that direction. Now what? . That knowledge is out there, and a number of people have it. I don't. I'm a clinician.
